Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 23 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Orlistat improves weight in obese adolescents

Orlistat improves weight management in obese adolescents compared with placebo, raising no safety issues, although gastrointestinal adverse events are more common with orlistat, reports the latest Journal of the American Medical Association.

News image

fiogf49gjkf04

The prevalence of overweight and obesity in children and adolescents is increasing rapidly.

In this population, behavioral therapy alone has had limited success in providing meaningful, sustained weight reduction.

Pharmacological treatment has not been extensively studied.

Body mass index decreased by 0.6 with orlistat but increased by 0.3 with placebo
Journal of the Medical Association

Dr Chanoine and colleagues determined the efficacy and safety of orlistat in weight management of adolescents.

The investigators conducted a multicenter, randomized, double-blind study at 32 centers in the United States and Canada over 54 weeks from 2000 to 2002.

The investigative team included 539 obese adolescents, aged 12 to 16 years with a body mass index 2 units above the 95th percentile.

The team randomized 357 patients to 120 mg of orlistat or 182 to placebo 3 times daily for 1 year, plus a mildly hypocaloric diet, exercise, and behavioral therapy.

The main outcome measures included by the team were changes in body mass index.

The secondary measures included changes in waist and hip circumference, weight loss, lipid measurements, and glucose and insulin responses to oral glucose challenge.

The investigators found a decrease in body mass index in both treatment groups up to week 12.

After week 12, body mass index in both treatment groups stabilized with orlistat but increased beyond baseline with placebo.

The investigative team found that at the end of the study, body mass index had decreased by 0.6 with orlistat but increased by 0.3 with placebo.

Compared with 16% of the placebo group, the team reported that 27% of participants taking orlistat had a 5% or higher decrease in body mass index.

The investigators also observed that 5% with placebo and 13% receiving orlistat had a 10% or higher decrease in body mass index.

At study end, the investigative team noted that weight had increased 0.5 kg with orlistat and 3 kg with placebo.

The team explained that this difference in weight increase was due to changes in fat mass, shown by using dual-energy x-ray absorptiometry.

The investigators also reported that waist circumference decreased in the orlistat group but increased in the placebo group.

In addition, mild to moderate gastrointestinal tract adverse events were identified in 9% to 50% of the orlistat group and in 1% to 13% of the placebo group.

Dr Chanione and team concluded, “In combination with diet, exercise, and behavioral modification, orlistat statistically significantly improved weight management in obese adolescents compared with placebo.”

“The use of orlistat for 1 year in this adolescent population did not raise major safety issues although gastrointestinal adverse events were more common in the orlistat group.”

JAMA 2005: 293: 2873-83
17 June 2005

Go to top of page Email this page Email this page to a colleague

 23 November 2017 
Distance travelling for rectal cancer outcomes
 23 November 2017 
Incidence of biopsy-verified celiac disease
 23 November 2017 
Pharmacological management of GERD
 22 November 2017 
Surgical treatment delays influence survival in colon cancer
 22 November 2017 
Golimumab in Crohn's disease
 22 November 2017 
Challenges of US-trained gastroenterologists when abroad
 21 November 2017 
Prepregnancy obesity and maternal mortality
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 15 November 2017 
Medication nonadherence and health care costs
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Heartburn relief in adolescents with GERD
 01 November 2017 
Autoimmune pancreatitis in children
 31 October 2017 
Follow-up of positive results on fecal blood tests
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's
 26 October 2017 
Conversion to open laparotomy in rectal cancer
 25 October 2017 
Conversion of colonoscopy to sigmoidoscopy
 25 October 2017 
Rifaximin and survival in hepatic encephalopathy

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us